Article Text

Download PDFPDF
CASE REPORT
Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome
  1. Pierrick Henneton1,
  2. Anne Legrand2,
  3. Cecilia Giunta3,
  4. Michael Frank4
  1. 1Médecine Interne et Vasculaire, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France
  2. 2Service de Génétique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
  3. 3Division of Metabolism, Connective Tissue Unit, University Children’s Hospital Zurich, Zurich, Switzerland
  4. 4Centre de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
  1. Correspondence to Dr Michael Frank, michael.frank{at}aphp.fr

Summary

Pathogenic variants in the lysyl-hydroxylase-1 gene (PLOD1) are responsible for the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS). The disease is classically responsible for severe hypotonia at birth, progressive kyphoscoliosis, generalised joint hypermobility and scleral fragility. Arterial fragility is an important feature of the disease, but its characterisation remains limited. We report the clinical history of a 41-year-old woman who presented repeated arterial accidents, which occurred in previously normal medium size arteries within a limited time span of 2 years. Molecular investigations revealed compound heterozygosity for two PLOD1 gene deletions of exons 11–12 and 14–15. Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms which may occur even during early childhood. This fragility is particularly likely to manifest during surgical intervention. Early medical management and surveillance may be indicated, but its modalities remain to be defined.

  • cardiovascular medicine
  • genetics

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors HP and MF wrote the paper, CG ensured biochemical analysis and AL molecular analysis.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.